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Abstract 
Background: This study explores the association of demographic and clinical features with quality of life and func‑
tioning in individuals with bipolar disorder.
Methods: Adult participants (N = 482) with bipolar I or II disorder were enrolled in a comparative effectiveness study 
across eleven study sites and completed baseline measures of medical and psychiatric history, current mood, quality 
of life, and functioning. Participants with at least mildly depressive or manic/hypomanic symptomatic severity were 
randomized to receive lithium or quetiapine in addition to adjunctive personalized treatment for 6 months.
Results: Participants with more severe depressive and irritability symptoms had lower quality of life and higher func‑
tional impairment. All psychiatric comorbid conditions except substance use disorder were associated with worse 
quality of life. On average, females had lower quality of life than males. Patients who were married, living as married, 
divorced, or separated had worse functional impairment compared with patients who were single or never married. A 
composite score of social disadvantage was associated with worse functioning and marginally associated with worse 
quality of life. Symptom severity did not moderate the effect of social disadvantage on quality of life or functioning.
Conclusions: Our findings highlight that depression, irritability, and psychiatric comorbid conditions negatively 
impact quality of life and functioning in bipolar disorder. The study suggests that individuals with social disadvantage 
are at risk for functional impairment.
Trial Registration This study is registered with ClinicalTrials.gov. Identification number: NCT01331304
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Background
Individuals with bipolar disorder frequently experience 
lower quality of life and worse functioning than the gen-
eral population (Abraham et al. 2014; Sierra et al. 2005; 
Sylvia et al. 2013), even when not in a mood episode (Ful-
ford et al. 2014; Gazalle et al. 2007; Shabani et al. 2013). 
Moreover, those who experience a lower quality of life 
exhibit higher inter-episode impulsivity and more cogni-
tive impairment as well as residual depressive and psy-
chotic symptoms (Depp et al. 2006; Victor et al. 2011).
Beyond psychiatric symptoms, other sources of stress 
could contribute to lower quality of life and function-
ing. One complex construct that might explain these 
deficits is social disadvantage. Social disadvantage is 
a composite measure composed of education level, 
employment status, income level, and occupational 
prestige (Duncan 1961). Bipolar disorder is associ-
ated with higher rates of unemployment and disability 
(Fulford et al. 2014; Sanchez-Moreno et al. 2009; Sylvia 
et  al. 2013), and greater social disadvantage has been 
associated with higher levels of stress, higher mortality, 
and decreased access to healthcare (Adler and Newman 
2002; Brennan et  al. 2013; Mielck et  al. 2014). Thus, 
it remains unclear as regards the association of social 
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disadvantage with quality of life and functioning in 
bipolar disorder.
The purpose of this paper is to explore the determi-
nants of quality of life and functioning, especially the 
construct of social disadvantage, in a representative 




We enrolled 482 participants across eleven study sites 
for a comparative effectiveness trial [Bipolar CHOICE 
study—(Nierenberg et  al. 2014)] that compared lithium 
with quetiapine in addition to adjunctive personalized 
treatment. The main inclusion criteria were being at least 
18  years of age; having a primary diagnosis of bipolar I 
or II disorder; and being at least mildly symptomatic, 
either depressed, or manic/hypomanic. Participants were 
excluded if they were currently a psychiatric or medical 
inpatient, or had a history of failed treatment response to 
lithium or quetiapine, current lithium or quetiapine usage, 
and any contraindication to either medication (e.g., severe 
cardiovascular disease, renal disease, or pregnancy).
Study design
The clinical and health outcomes initiative in comparative 
effectiveness for bipolar disorder study (Bipolar CHOICE) 
was a 6-month, parallel group, randomized controlled trial 
that compared the effectiveness of a second generation 
antipsychotic (quetiapine) and a classic mood stabilizer 
(lithium) (Nierenberg et  al. 2014). Each group received 
adjunctive personalized treatments (APTs), or any other 
medications as needed, except the quetiapine group 
(QTP + APT) could not be prescribed lithium (Li + APT) 
or other antipsychotics and the lithium group could not be 
prescribed antipsychotics. APTs allow for greater general-
izability and flexibility, as opposed to the strict monother-
apy that patients typically receive in standard comparative 
effectiveness trials. APT was both evidence based and per-
sonalized to current symptoms, prior treatment history, 
and course of illness (Suppes et al. 2005).
Patients completed baseline measures assessing medi-
cal and psychiatric history as well as current mood, qual-
ity of life, and functioning and were then randomized to 
either Li + APT or QTP + APT. This report focuses on 
the baseline measures related to the quality of life.
Measures
The mini international neuropsychiatric interview (Sheehan 
et al. 1997) (MINI 6.0)
The mini international neuropsychiatric interview is a 
clinician-administered, semistructured diagnostic inter-
view that was designed specifically for clinical trials and 
epidemiological studies (Sheehan et  al. 1997). The MINI 
was administered at the baseline visit to determine diagno-
ses, which correspond to DSM-IV-TR or ICD-10 diagnoses.
Quality of life, enjoyment, and satisfaction questionnaire 
(Endicott et al. 1993) (Q‑LES‑Q)
The Q-LES-Q is a self-report measure that assesses sub-
jective quality of life (i.e., physical health, subjective feel-
ings, leisure activities, and social relationships) over the 
previous week. Participants rate items on a scale from a 
5-point scale that ranges from “very poor” to “very good.”
Longitudinal interval follow‑up evaluation—range 
of impaired functioning tool (Leon et al. 2000) (LIFE‑RIFT)
The LIFE-RIFT assesses the extent to which psychopathol-
ogy has impacted current functioning in work, household 
chores, interpersonal relationships with partner, family, 
and friends, recreational activities, and life satisfaction. A 
reliable and valid measure of functioning, the LIFE-RIFT, 
assesses impairment in four areas—work (employment, 
household, school), interpersonal relationships (spouse, 
child, other relatives, friends), satisfaction, and recreation.
Social disadvantage
Social disadvantage was defined as the sum of three 
dichotomous variables: household income (1 if less than 
$25,000, 0 if $25,000 or more), education status (1 if 
highest level was high school or less, 0 if at least some 
college), and employment status (1 if unemployed/
disabled, 0 if employed/student/retired). We omitted 
occupational prestige in the study’s definition of social 
disadvantage as it was not assessed given the subjectivity 
of this component and that prestige likely varies for this 
clinical population (i.e., based on high rates of disability, 
any job could, and probably should, be prestigious for an 
individual with bipolar disorder) (Oakes and Rossi 2003). 
It has been widely noted that low socioeconomic status 
is correlated with psychiatric illness and higher rates of 
disability (Hirschfeld et al. 2003; Lorant et al. 2003).
Bipolar inventory of symptoms scale (Bowden et al. 2007)
The BISS is a clinician-administered, structured inter-
view that was originally developed with a focus on 
assessing bipolar symptoms in an outpatient sample. 
Items are assessed on a 5-point Likert scale, 0 indicat-
ing not at all to 4 indicating severe. The BISS measures 
the domains of mania, depression, irritability, anxiety, 
and psychosis (Thompson et  al. 2010). BISS domain 
scores were re-scaled to range from 0 to 40.
Statistical analysis
Descriptive data at baseline were reported as frequen-
cies or mean with standard deviation. Linear regression 
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models were fit to explore whether baseline quality of life 
(Q-LES-Q) and functioning (LIFE-RIFT) were associ-
ated with baseline demographics, clinical severity, social 
disadvantage, and current psychiatric comorbid condi-
tions. The composite score of social disadvantage (calcu-
lated based on household income, education level, and 
employment status) ranged from 0 to 3, corresponding, 
respectively, to no, mild, moderate, and severe disadvan-
tage. Variables (excluding comorbid conditions) were 
considered for inclusion in the multivariate linear regres-
sion model if univariate screening p value was less than 
0.25 and were ultimately included in the model if the 
adjusted p value was less than 0.05.
To explore whether clinical symptom severity (BISS 
total) moderated the effect of social disadvantage on 
quality of life and functioning, we fit linear regression 
models with main effects for disadvantage and clinical 
severity as well as their interaction. If the interaction was 
significant, we determined there to be evidence of mod-
eration. For these moderator analyses, we conducted a 
sensitivity analysis separating social disadvantage into 
each of its three components (rather than using the cat-
egorical composite score) to determine whether our 
conclusions were sensitive to this composite definition. 
Statistical analyses were performed using SAS 9.4 (Cary, 
NC, USA) and R version 3.2.1 (www.r-project.org).
Results
At baseline, the mean quality of life (Q-LES-Q) score was 
44.3 (SD = 17.8), and the mean functioning (LIFE-RIFT) 
score was 14.2 (SD =  3.4). The baseline associations of 
quality of life and functioning with demographics, clini-
cal severity, current psychiatric comorbid conditions, and 
social disadvantage are reported in Table 1. On average, 
females had lower quality of life than males. Patients who 
were married, living as married, divorced, or separated 
had worse functional impairment (higher scores on LIFE-
RIFT) compared with patients who were single or never 
married. Age, ethnicity, and race were not significantly 
related to quality of life or functioning.
Participants with greater clinical symptom severity 
measured with BISS (total, depression, anxiety, irritabil-
ity, and psychosis) had lower quality of life and higher 
functional impairment (Table  1). Patients with greater 
manic severity reported marginally better quality of life. 
No association was found between severity of manic 
symptoms and functioning. Only BISS depression and 
BISS irritability remained significant in both multivari-
ate models (Q-LES-Q and LIFE-RIFT). We also found 
that although most of the BISS symptom domains (anxi-
ety, irritability, depression, and psychosis) were associ-
ated with social disadvantage, mania was not (Table  2). 
In Fig.  1, we display the marginal (unadjusted) and 
conditional (adjusted for other covariate in model) effects 
of depressive and irritability symptom severity on quality 
of life and functioning. In both cases, the marginal and 
conditional effects of BISS depression were similar, while 
the effect of BISS irritability decreased when adjusting 
for BISS depression.
Social disadvantage was significantly associated with 
worse functioning and marginally associated with worse 
quality of life (p  =  0.07) (Table  1). Each component 
(income, education, and employment) was at least mar-
ginally associated with functioning, such that patients 
with lower income, lower education, and unemployed/
disabled had worse functioning (all p < 0.07). Those who 
were unemployed or disabled were marginally associ-
ated with lower quality of life (p = 0.06), whereas neither 
income nor education was significantly associated with 
quality of life.
All psychiatric comorbid conditions, except substance-
use disorder, were significantly associated with worse 
quality of life (Table  1). Panic disorder, agoraphobia, 
social disorder, ADHD, and any anxiety disorder were 
also associated with worse functional impairment. The 
total number of psychiatric comorbid conditions was 
associated with quality of life and functioning, such that 
for each additional comorbid condition, the mean quality 
of life decreased by 3.8 points and the mean functional 
impairment increased by 0.7 points (both p  <  0.001). 
We found no evidence to suggest that clinical symptom 
severity moderated the effect of social disadvantage on 
quality of life and functioning (both p > 0.05).
Discussion
Our results are consistent with earlier reports that show 
that individuals with bipolar disorder often experience 
overall poor quality of life and life functioning (Abraham 
et al. 2014; Sierra et  al. 2005; Sylvia et  al. 2013). We also 
found that females had lower quality of life than males. 
Patients who were married, living as married, divorced, 
or separated had worse functional impairment compared 
with patients who were single or never married. All psychi-
atric comorbid conditions, except substance-use disorder, 
were associated with worse quality of life. Panic disorder, 
agoraphobia, social disorder, ADHD, and any anxiety dis-
order were also associated with worse functional impair-
ment. These findings are consistent with previous studies 
examining comorbid conditions and functioning in bipo-
lar disorder (Mendlowicz and Stein 2000; Otto et al. 2006; 
Rapaport et al. 2005; Simon et al. 2004).
Social disadvantage was significantly associated with 
worse functioning and symptoms, but unexpectedly only 
marginally associated with quality of life. The multivariate 
models suggested that depression and irritability together 
were the strongest indicators of poor quality of life and 
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functioning in individuals with bipolar disorder. Consist-
ent with prior studies (Boylan et  al. 2004; McElroy et  al. 
2001; Simon et al. 2004), our findings suggest that current 
symptom severity and psychiatric comorbid conditions 
negatively impact quality of life and functioning in bipolar 
disorder.
Table 1 Baseline correlations of quality of life and functioning with demographics, clinical severity, social disadvantage, 
and current psychiatric comorbidities
Q-LES-Q quality of life enjoyment and satisfaction questionnaire, LIFE-RIFT longitudinal interval follow-up evaluation-range of impaired functioning tool, REF reference 
level, BISS bipolar inventory of symptoms scale, ADHD attention deficit hyperactivity disorder. Coefficients and p values based on linear regression models. Coefficients 
represent the change in Q-LES-Q/LIFE-RIFT per 1-point increase for continuous variables and change from reference level for categorical variables
a Includes patients with any of the following current diagnoses (based on MINI): panic disorder, agoraphobia, social phobia, and generalized anxiety disorder
Variable % (n) or mean + SD Q-LES-Q LIFE-RIFT
Coefficient p value Coefficient p value
Demographics
 Age 38.9 + 12.1 0.03 0.65 0.01 0.34
 Female (REF: male) 59% (283) −4.6 0.006 0.5 0.10
 Hispanic/Latino (REF: not) 11% (53) 2.1 0.43 0.6 0.21
 Race 0.94 0.83
  White 72% (348) REF REF
  Black 20% (96) −1.1 0.2
  Asian 3% (16) 0.7 0.1
  Native American <1% (1) 5.6 0.9
  Other 4% (21) 2.2 0.9
 Marital status 0.66 0.05
  Single/never married 47% (225) REF REF
  Married/living as married 31% (150) −2.1 0.9
  Divorced/separated 21% (100) −1.3 0.8
  Widowed 1% (7) 2.3 0.2
Clinical symptom severity
 BISS total 56.1 + 18.8 −0.46 <0.001 0.09 <0.001
 BISS depression 17.5 + 7.3 −1.64 <0.001 0.29 <0.001
 BISS mania 9.2 + 6.4 0.23 0.08 −0.03 0.29
 BISS anxiety 15.9 + 8.5 −0.92 <0.001 0.17 <0.001
 BISS irritability 16.8 + 8.5 −0.65 <0.001 0.15 <0.001
 BISS psychosis 2.8 + 4.5 −0.48 0.007 0.15 <0.001
Social disadvantage
 Household income <$25 K (REF: ≥25 K) 52% (249) −1.7 0.30 0.6 0.06
 High school diploma or less (REF: at least some college) 25% (122) −2.0 0.29 0.8 0.03
 Unemployed/disabled (REF: employed/student/retired) 51% (244) −3.1 0.06 0.7 0.03
Social disadvantage 0.07 0.03
 No disadvantage 28% (133) REF REF
 Mild 30% (142) −1.1 0.6
 Moderate 29% (138) −5.3 0.8
 Severe 13% (65) −2.2 1.4
Current psychiatric comorbidity
 Generalized anxiety disorder 22% (107) −5.9 0.002 0.6 0.11
 Substance use disorder 23% (109) −0.6 0.76 0.2 0.49
 Obsessive–compulsive disorder 11% (51) −4.9 0.02 0.9 0.08
 Panic disorder 23% (112) −8.7 <0.001 0.8 0.03
 Agoraphobia 37% (176) −5.8 0.001 0.9 0.003
 Social disorder 25% (119) −5.3 0.005 0.8 0.03
 ADHD 34% (161) −4.2 0.02 1.0 0.002
 Any anxiety disordera 58% (277) −8.9 <0.001 1.2 <0.001
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These results support findings in other clinical popula-
tions that social disadvantage can have a negative effect 
on the overall functioning of individuals with bipolar dis-
order (Bowie et al. 2010; Huxley and Baldessarini, 2007; 
Judd and Akiskal 2003). Social disadvantage has been 
associated with higher levels of stress, greater likelihood 
of depression, and higher rates of disability (Lorant et al. 
2003). Given the frequency of depression and irritabil-
ity as well as severity of these symptoms in this clinical 
population, it is perhaps not surprising that these symp-
toms were primarily associated with social disadvantage 
among individuals with bipolar disorder; however, we 
expected that mania would correlate with this outcome 
Table 2 Association between  BISS symptom domains 
and social disadvantage
REF reference level
a Pairwise comparison with 0-REF is significant (p < 0.05)
Social disadvantage score Overall
0-REF 1 2 3 p value
BISS domain score
 Depression 16.3 + 7.1 16.7 + 7.1 18.6 + 7.7a 19.3 + 7.0a 0.006
 Mania 8.13 + 5.9 9.2 + 6.8 9.9 + 6.9 9.4 + 4.8 0.15
 Anxiety 13.8 + 8.0 15.6 + 8.3 17.0 + 9.0a 18.3 + 8.4a 0.001
 Irritability 15.9 + 8.3 15.2 + 8.3 17.7 + 8.9 20 + 7.9a 0.0006
 Psychosis 1.7 + 3.2 2.6 + 4.3 3.5 + 5.4a 4.0 + 4.6a 0.0006
Fig. 1 Marginal and conditional effects of depression and irritability on quality of life and functioning. In this figure, we display the marginal 
(unadjusted) and conditional (adjusted for other covariate in model) effects of depressive and irritability symptom severity on quality of life and 
functioning. In both cases, the marginal and conditional effects of BISS depression were similar, while the effect of BISS irritability decreased when 
adjusting for BISS depression
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given the degree to which these symptoms can dis-
rupt one’s functioning (e.g., ability to work, obtain high 
incomes). It is likely that we did not find this correlation 
as most participants were depressed (opposed to manic) 
throughout the duration of the study (Tohen et al. 2015) 
(see Table 1).
Interestingly, while patients with greater clinical sever-
ity (i.e., total, depression, anxiety, irritability) had lower 
quality of life, patients with greater manic severity 
reported marginally better quality of life. No association 
was found between manic severity and functioning, con-
sistent with the literature (Rosa et  al. 2010), and mania 
was not associated with social disadvantage. These find-
ings could be explained by the use of a self-report meas-
ure of quality of life as this relies on the insight and 
perception of the individual, which are often altered dur-
ing this mood state with grandiosity and expansiveness. 
This study is unique in its analysis of the association of 
mood symptoms with social disadvantage in a large sam-
ple of bipolar I and bipolar II patients; however, it should 
be noted that education and employment (two compo-
nents of social disadvantage) are potentially overlapping 
constructs of quality of life and functioning. Further, 
the limited inclusion and exclusion criteria may have 
enhanced generalizability of our findings. However, these 
participants were recruited for a study at academic medi-
cal centers, and thus, replication in community settings is 
warranted.
Conclusions
Individuals with bipolar disorder commonly report poor 
quality of life and have difficulty functioning. This study 
also sought to explore those who might be at greater 
risk for poor outcomes by examining the impact of a 
composite variable of several, overlapping demographic 
aspects, or social disadvantage. It appears that depres-
sion and irritability (but not mania) worsen quality of life 
and functioning in this clinical population. Overall, these 
data suggest that better interventions for individuals 
with social disadvantage, depression, and irritability are 
needed as they may be at greater risk for improvement in 
quality of life and functioning.
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